Journal of Nanomaterials & Molecular NanotechnologyISSN: 2324-8777

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Kouros Motamed Author

kmotamed@sorrentotherapeutics.com 1-949-988-7920 | 1-949-988-79

Subjects of specialization
Cancer Cells, Signaling Pathways, Cell Migration, Cell Signaling, Cancer Biology

Affiliation
IGDRASOL Inc. One Technology Dr. Suite J-729, Irvine, CA, USA

Biography

Kouros Motamed currently works at NantBioscience as Director of Drug Development. His group is responsible for design and execution of IND-enabling studies for in-house and licensed small molecules and biologics. Their most recent publication is 'IG-001 ? A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors'.

Publications

Research Article Subscription

IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors

Author(s):

Kouros Motamed, Yin Goodman, Larn Hwang, Chao Hsiao and Vuong Trieu

IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors

nab-paclitaxel (Abraxane®)—a Cremophor-free, albumin-bound, nanoparticle form of paclitaxel—though a breakthrough in paclitaxel formulation, has inherent problems associated with any biologics. IG-001 (Genexol-PM®), a polymeric micellar formulation forms nanoparticles with paclitaxel containing a hydrophobic core and a hydrophilic shell and is being developed as the next generation nanoparticle paclitaxel. Its target indication... view more»

DOI: 10.4172/2324-8777.1000136

Abstract HTML PDF

Social Media

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP